1. Appendix: Publications
1. Preparation of heteroaryl compounds as Kynurenine-3-monooxygenase
inhibitors for treatment of neurodegenerative disorders. Dominguez, Celia;
Toledo-Sherman, Leticia M.; Prime, Michael; Mitchell, William; Went, Naomi; PCT
Int. Appl. (2015), WO 2015047978 A1 20150402.
2. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and
methods of use. Dominguez, Celia; Toledo-Sherman, Leticia M.; Prime,
Michael; Mitchell, William; Went, Naomi; PCT Int.
Appl. (2015), WO 2015047982 A2 20150402.
3. Development of a Seriesof Aryl Pyrimidine Kynurenine Monooxygenase
Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s
Disease, Toledo-Sherman, L.M.; Prime, M. E.; Mrzljak, L.; Beconi, M. G.;
Beresford, A.; Brookfield, F. A.; Brown, C. J.; Cardaun, I.; Courtney, S.M.;
Dijkman, U.; Hamelin-Flegg, E.; Johnson, P. D.; Kempf, V.; Lyons, K.; Matthews, K.;
Mitchell, W. L.; O’Connell, C.; Pena, P.; Powell, K.; Rassoulpour, A.; Reed, L.;
Reindl, W.; Selvaratnam, S.; Friley, W. W.; Weddell, D. A.; Went, N. E.; Wheelan, P.;
Winkler, C.; Winkler, D.; Wityak, J.; Yarnold, C. J.; Yates, D.; Munoz-Sanjuan, I.;
Dominguez, C.; J. Med. Chem., 2015, 58,1159–1183.
4. CHDI-00340246, A Kynurenine Monooxygenase Inhibitor as Potential
Therapeutic Agent for the Treatment of Huntington’s Disease. Toledo-Sherman,
L. M.; Prime, M.; Mitchell, W.; Brown, C.J.; Gaines, S.; Johnson, P.; Pena, P.; Reed,
L.; Sehmi, S.; Selvaratnam, S.; Winkler, D.; Beconi, M.; Lyons, K.; Rassoulpour, A.;
Dijkman, U.; Powell, K.; Ward, W.; Kempf, V.; Wheelan, P.; Yates, D.; Matthews, K.;
Mrzljak, L.; Munoz-Sanjuan, I.; Dominguez, C.; Journal of Neurology Neurosurgery &
Psychiatry 09/2014; 85(Suppl 1):A2-A3.
5. Preparation of phenylcyclopropyl carboxylic acids and similar compounds as
kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions
containing same, and use in treating neurodegenerative disorders. Toledo-
Sherman, L. M.; Dominguez, C.; Prime, M.; Mitchell, W. L.; Johnson, P.; Went, N.;
World Patent 2013151707 (2013).
6. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-
secretase modulators reduced amyloidogenic Aβ peptides in vivo. Huang, Y.; Li,
T.; Eatherton, A.; Mitchell, W. L.; Rong, N.; Ye, L.; Yang, X-J.; Jin, S.; Ding, Y.;
Zhang, J.; et al; Neuropharmacology, 2013, 70, 278-286.
7. Preparation of phenylpyrimidinylcarboxylic acid derivatives and analogs for
use as kynurenine-3-monooxygenase inhibitors. Courtney, S. M.; Prime, M.;
Mitchell, W.; Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P.; Dominguez, C.;
Toledo-Sherman, L. M.; Munoz, I.; PCT Int.
Appl. (2013), WO 2013033085 A1 20130307
8. Preparation of phenylpyrimidine derivatives and analogs for use as kynurenine -
3-monooxygenase inhibitors. Courtney, S. M.; Prime, M.; Mitchell, W.; Brown, C.
J.; De Aguiar Pena, P. C.; Johnson, P.; Dominguez, C.; Toledo-Sherman, L. M.;
Munoz, I.; PCT Int. Appl. (2013), WO 2013033068 A1 2013030725.
9. Certain pyrimidine derivatives as kynurenine-3-monooxygenase inhibitors,
pharmaceutical compositions, and methods of use and preparation thereof
Dominguez, C.; Toledo-Sherman, L. M.; Courtney, S. M.; Prime, M.; Mitchell, W.;
Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P.; PCT Int. Appl. (2013),
2013016488 A1 20130131.

2. 10. KMO inhibitors as potential therapeutic agents for the treatment of HD:
Towards proof-of-concept studies. Prime, M.; Winkler, D.; Beconi, M.; Brookfield,
F.; Brown, C.; Courtney, S.; Ebneth, A.; Grigg, R.; Hamelin-Flegg, E.; Johnson, P.;
Mack, V.; Marston, R.; Mitchell, W.; Pena, P.; Reed, P.; Suganthan, S.; Munoz-
Sanjuan, I.; Schaeffer, E.; Toledo-Sherman, L.; Weddell, D.; Went, N.; Winkler, C.;
Wityak, J.; Yarnold, C.; Dominguez, C., Evotec (UK) Ltd, Abingdon, UK; Abstracts
of Papers, 242nd ACS National Meeting & Exposition, Denver, CO, United States,
August 28-September 1, 2011 (2011), MEDI-330.
11. Pyridine-derived γ-secretase modulators. Wan, Z.; Hall, A.; Sang, Y.; Xiang, J-
N.; Yang, E.; Smith, B.; Harrison, D.C.; Yang, G.; Yu, H.; Price, H.S.; Wang, J.;
Hawkins, J.; Lau, L-F.; Johnson, M.R.; Li, T.; Zhao, W.; Mitchell, W.L.; Su, X.; Zhang,
X.; Zhou, Y.; Jin, Y.; Tong, Z.; Cheng, Z.; Hussain, I.; Elliott, J.D.; Matsuoka, Y.;
Bioorg. Med. Chem. Lett., 2011, 21, 4832-4835.
12. Pyridazine-derived γ-secretase modulators. Wan, Z.; Hall, A.; Jin, Y.; Xiang, J-
N.; Yang, E.; Eatherton, A.; Smith, B.; Yang, G.; Yu, H.; Wang, J.; Ye, L.; L., Lit-Fui;
Ying, T.; Mitchell, W.; Cai, W.; Zhang, X.; Sang, Y.; Wang, Y.; Tong, Z.; Cheng, Z.;
Hussain, I.; Elliott, J.D..; Matsuoka, Y.; Bioorg. Med. Chem. Lett., 2011, 21, 4016-
4019.
13. Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB2
agonists for the treatment of inflammatory pain. Gleave, R.J.; Beswick, P.J.;
Brown, A.J.; Giblin, G.M.P.; Goldsmith, P.; Haslam, C.P.; Mitchell, W.L.; Nicholson,
N.H.; Page, L.W.; Patel, S.; Roomans, S.; Slingsby, B.P.; Swarbrick, M.E.; Bioorg.
Med. Chem. Lett., 2010, 20, 465-468.
14. An enantiopure pseudo-C3-symmetric titanium triflate with propeller-like
chirality as a catalyst for asymmetric sulfoxidation reactions. Axe, P.; Bull,
S.D.; Davidson, M.G.; Jones, M.D.; Robinson, D.E.J. E.; Mitchell, W.L.; Warren, J.E.;
Dalton Transactions, 2009, 46, 10169-10171.
15. Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-
yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole
CB2 Agonist for the Treatment of Chronic Pain. Giblin, G.M.P.; Billinton, A.;
Briggs, M.; Brown, A.J.; Chessell, I.P.; Clayton, N.M.; Eatherton, A.J.; Goldsmith, P.;
Haslam, C.; Johnson, M.R.; Mitchell, W.L.; Naylor, A.; Perboni, A.; Slingsby, B.P.;
Wilson, A.W.; J. Med. Chem., 2009, 52, 5785-5788.
16. Pyridazine derivatives for inhibiting β-amyloid peptide production and their
preparation, pharmaceutical compositions and use in the treatment of
Alzheimer's disease. Eatherton, A.J.; Giblin, G.M.P; Hall, A.; Johnson, M.R.; Le, J.;
Mitchell, W.L.; Myatt, J.; Norton, D.; Price, H.S.; World Patent 2009050227 (2009).
17. Pyridine-3-carboxamides as novel CB2 agonists for analgesia. Mitchell, W.L.;
Giblin, G.M.P.; Naylor, A.; Eatherton, A.J.;Slingsby, B.P.; Rawlings, A.R.; Jandu,
K.S.; Haslam, C.P.; Brown, A.J.;Goldsmith, P.; Clayton, N.M.; Wilson, A.W.;
Chessell, I.P.; Green, R.H.; Whittington, A.R.; Wall, I.D.; Bioorg. Med. Chem. Lett.,
2009, 17, 259-263.
18. Pyridine-3-carboxamides as novel CB2 agonists for analgesia. Mitchell, W.L.;
Giblin, G.M.P.; Naylor, A.; Eatherton, A.J.;Slingsby, B.P.; Rawlings, A.R.; Jandu,
K.S.; Haslam, C.P.; Brown, A.J.;Goldsmith, P.; Clayton, N.M.; Wilson, A.W.;
Chessell, I.P.; Green, R.H.; Whittington, A.R.; Wall, I.D.; Poster Presentation for
GPCRs in Medicinal Chemistry, Gothenburg, Sweden, 2008, 8-10 September.
19. Synthetic approaches to novel, functionalised 5- and 6-azaindoles Johnson,
M.R.; Eatherton, A.J.; Giblin, G.M.P.; Mitchell, W.L.; Perboni, A.; Slingsby, B.P.;

3. Poster Presentation for UK-Singapore Symposium on Contemporary Organic
Synthesis, Methods, and Techniques, Biopolis, Singapore, 2008, 24-27 February.
20. Preparation of pyrrolopyrazines as cannabinoid receptor modulators.
Eatherton, A.J.; Giblin, G.M.P.; Mitchell, W.L. World Patent 2007088168 (2007).
21. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-
yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2
Receptor Agonist for the Treatment of Inflammatory Pain. Giblin, G.M.P.;
O'Shaughnessy, C.T.; Naylor, A.; Mitchell, W.L.; Eatherton, A.J.; Slingsby, B.P.;
Rawlings, D.A.; Goldsmith, P.; Brown, A.J.; Haslam, C.P.; Clayton, N.M.; Wilson,
A.W.; Chessell, I.P.; Wittington, A.R.; Green, R.; J. Med. Chem., 2007, 50, 2597-
2600.
22. Preparation of arylpyridazines as cannabinoid CB2 receptor agonists.
Gleave, R.; Mitchell, W.L.; Page, L.W.; Swarbrick, M.; Walters, D.J. World Patent
2007022938 (2007).
23. Preparation of pyridazines as modulators of cannabinoid CB2 receptors.
Gleave, R.; Mitchell, W.L.; Page, L.W.; Swarbrick, M. World Patent 2007022937
(2007)
24. Preparation of 1H-pyrrolo[3,2-c]pyridine derivatives and their activity as
cannabinoid receptor agonists. Eatherton, A.J.; Giblin, G.M.P.; Jandu, K.S.;
Johnson, M. R.; Mitchell, W.L.; Naylor, A.; Sweeting, J.A. World Patent 2007017264
(2007).
25. Preparation of imidazopyridine derivatives as cannabinoid receptor ligands.
Eatherton, A. J.; Giblin, G.M.P.; Mitchell, W.L.; Naylor, A.; Page, L.W.; Swarbrick, M.;
Sweeting, J.A. World Patent 2007017237 (2007).
26. Enantiopure Pseudo-C3-Symmetric Titanium Alkoxide with Propeller-Like
Chirality. Axe, P.; Bull, S.D.; Davidson, M.G.; Gilfillan, C.J.; Jones, M.D.;
Robinson, D.E.J.E.; Turner, L.E.; Mitchell, W.L.; Organic Letters, 2007, 9, 223-226.
27. Preparation of pyrrolopyridine derivatives as cannabinoid receptor modulators.
Eatherton, A.J.; Giblin, G.M.P.; Johnson, M.R.; Mitchell, W.L.; Perboni, A.; Slingsby,
B.P. World Patent 2005121140 (2005).
28. Preparation of pyrimidine derivatives as cannabinoid receptor modulators.
Eatherton, A.J.; Giblin, G.M.P.; Mitchell, W.L.; Naylor, A. World Patent 2005080350
(2005).
29. Preparation of pyrimidine derivatives as agonists of cannabinoid receptors for
the treatment of pain. Giblin, G.M.P.; Mitchell, W.L.; Naylor, A.; Wall, I.D. World
Patent 2005080349 (2005).
30. Preparation of pyridine derivatives as CB2 receptor modulators. Eatherton,
A.J.; Giblin, G.M.P.; Mitchell, W.L.; Naylor, A. World Patent 2005080342 (2005).
31. Preparation of carbamoyl-amino-pyridine derivatives as cannabinoid receptor
modulators. Giblin, G.M.P.; Jandu, K.S.; Mitchell, W.L.; Wall, I.D. World Patent
2005075464 (2005).
32. Preparation of 2-(phenylamino)-pyrimidin-5-amides as cannabinoid 2 receptors
modulators for the treatment of immune or inflammatory disorders.
Eatherton, A.J.; Giblin, G.M.P.; Mitchell, W.L.; Naylor, A.; Rawlings, D.A.; Wall, I.D.
World Patent 2005075440 (2005).
33. Preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in

4. combination with PDE4 inhibitors for treating pain, immune, inflammatory and
rheumatic diseases. Green, R.H.; Brown, A.J.; Connor, H.E.; Eatherton, A.J.;
Giblin, G.M.P.; Jandu, K.S.; Knowles, R.G.; Mitchell, W.L.; Naylor, A.;
O'Shaughnessy, C.; Palombi, G.; Rawlings, D.A; Slingsby, B.P.; Tralau-Stewart, C.J.;
Whittington, A.R.; Williamson, R.A. World Patent 2005074939 (2005).
34. Novel pyrimidine CB2 receptor agonists for inflammatory pain. Giblin, G.M.
P.; O'Shaughnessy, C.; Naylor, A.; Mitchell, W.L.; Eatherton, A.J.; Jandu, K;
Rawlings, T.; Slingsby, B.; Sweeting, J.; Wall, I.; Goldsmith, P.; Brown, A.J.; Haslam,
C.; Wilson, A.; Clayton, N.; Whittington, A.; Green, R. Abstracts of Papers, 229th
ACS National Meeting, San Diego, CA, United States, March 13-17, 2005 (2005),
MEDI-005.
35. Preparation of pyridine derivatives as CB2 receptor modulators. Green, R.H.;
Eatherton, A.J.; Giblin, G.M.P.; Jandu, K.S.; Mitchell, W.L.; Naylor, A.; Palombi, G.;
Rawlings, D.A.; Slingsby, B.P.; Whittington, A.R. World Patent 2004029026 (2004).
36. Preparation of substituted pyridine derivatives as CB2 receptor modulators.
Green, R.H.; Eatherton, A.J.; Giblin, G.M.P.; Jandu, K.S.; Mitchell, W.L.; Naylor, A.;
Palombi, G.; Rawlings, D.A.; Slingsby, B.P.; Whittington, A.R. World Patent
2004029027 (2004).
37. Preparation of pyrimidinylcarboxamide compounds as cannabinoid receptor
agonist and their use for treatment of pain. Eatherton, Andrew John; Giblin,
Gerard Martin Paul; Green, Richard Howard; Mitchell, William Leonard; Naylor, Alan;
Rawlings, Derek Anthony; Slingsby, Brian Peter; Whittington, Andrew Richard. World
Patent 2004018434 (2004).
38. Preparation of aminopyrimidinecarboxamidesand their use as CB2-type
cannabinoid receptor modulators. Eatherton, A.J.; Giblin, G.M.P.; Green, R.H.;
Mitchell, W.L.; Naylor, A.; Rawlings, D.A.; Slingsby, B.P.; Whittington, A.R. World
Patent 2004018433 (2004).
39. Synthesis of 2-hydroxy-8'-(hydroxymethyl)-1,1'-binaphthalene (iso-homo-binol).
A new structural pattern in the binaphthyl realm. Vyskocil, S.; Lockhart, S.C.;
Mitchell, W.L.; Kocovsky, P.; Collect. Czech. Chem. Commun. 2003, 68, 907-916
40. 2,8'-disubstituted-1,1'-binaphthyls: a new pattern in chiral ligands. Vyskocil,
S.; Meca, L.; Tislerova, I.; Cisarova, I.; Polasek, M.; Harutyunyan, S.R.; Belokon,
Y.N.; Stead, R.M.J.; Farrugia, L.; Lockhart, S.C.; Mitchell, W.L.; Kocovsky, P.; Chem.
Eur. J. 2002, 8, 4633-4648.
41. Thrombin inhibitors based on [5,5] trans-fused indane lactams. Pass, M.;
Abu-Rabie, S.; Baxter, A.; Conroy, R.; Coote, S.J.; Craven, A.P.; Finch, H.; Hindley,
S.; Kelly, H.A.; Lowdon, A.W.; McDonald, E.; Mitchell, W.L.; Pegg, N.A.; Procopiou,
P.A.; Ramsden, N.G.; Thomas, R.; Walker, D.A.; Watson, N.S.; Jhoti, H.; Mooney, C.
J.; Tang, C-M.; Thomas, P.J.; Parry, S.; Patel, C; Bioorg. Med. Chem. Lett. 1999, 9,
1657-1662.
42. Molybdenum(II)-Catalyzed Allylation of Electron-Rich Aromatics and
Heteroaromatics. Malkov, A.V.; Davis, S.L.; Baxendale, I.R.; Mitchell, W.L.;
Kocovsky, P.; J. Org. Chem. 1999, 64, 2751-2764
43. Preparation of piperidinylvinylindazolylpiperidineacetatesasinhibitors of
fibrinogen-dependent platelet aggregation. Allen, D.G.; Eldred, C.D.; Judkins,
B.D.; Mitchell, W.L. World Patent 9749699 (1997).
44. Preparation of 4-heterocyclyl-1-piperidineacetates as glycoprotein IIb/IIIa
receptor antagonists. Allen, D.G.; Eldred, C.D.; Judkins, B.D.; Mitchell, W.L.;
Scopes, D.I.C. World Patent 9749698 (1997).

5. 45. Molybdenum(II)-catalyzed alkylation of electron-rich aromatics with allylic
acetates. Malkov, A.V.; Davis, S.L.; Mitchell, W.L.; Kocovsky, P.; Tetrahedron
Lett. 1997, 38, 4899-4902.
46. Preparation of indazolylpiperidineacetates as fibrinogen antagonists. Allen,
D.G.; Eldred, C.D.; Mitchell, W.L. World Patent 9620192 (1996).
47. Selective reduction of the carbonyl group in organomercurials. A facile method
for the protection-deprotection of the mercurio group and a new route to
annulated lactones. Kocovsky, P.; Dunn, V.; Grech, J.M.; Srogl, J.; Mitchell,
W.L.; Tetrahedron Lett. 1996, 37, 5585-5588.
48. A stereoselective synthesis of cis- and trans-fused lactones via the
palladium(II)-catalyzed carbonylation of organomercurials. Kocovsky, P.;
Grech, J.M.; Mitchell, W.L.; Tetrahedron Lett. 1996, 37, 1125-8.
49. Preparation of aniline and benzanilide derivativesas 5-HT1D antagonists.
Mitchell, W.L.; Bradshaw, B.; Clitherow, J.W.; Carter, M. Brit. UK Pat. Appl. GB
2276161 (1994).
50. Preparation of aniline and benzanilide compounds as 5-HT1D antagonists.
Mitchell, W.L.; Bradshaw, J.; Oxford, A.W.; Clitherow, J.W. Brit. UK Pat. Appl.
2276165 (1994).
51. Cupration of Organomercurials: A Mild Method for the Intramolecular Addition
of Organometallics to Ester Groups. Kocovsky, P.; Grech, J.M.; Mitchell, W.L.;
J. Org. Chem. 1995, 60, 1482-3.
52. Preparation of pyridine compounds. Mitchell, W.L.; Clitherow, J.W. Brit. UK
Pat. Appl. 2276163 (1994).
53. Evolution of a Novel Series of [(N,N-Dimethylamino)propyl]- and
Piperazinylbenzanilidesas the First Selective 5-HT1D Antagonists. Clitherow, J.
W.; Scopes, D.I.C.; Jordan, C.J.; Feniuk, W.; Campbell, I.B.; Carter, M.C.; Collington,
E.W.; Connor, H.E.; Higgins, G.A.; Beattie, D.; Kelly, H.A.; Mitchell, W.L.; Oxford,
A.W.; Wadsworth, A.H.; Tyers, M.B.; J.Med. Chem. 1994, 37, 2253-2257.
54. Aniline and benzanilide derivatives. Scopes, D.I.C.; Clitherow, J.W.; Mitchell,
W.L.; Carter, M. Brit. UK Pat. Appl. 2276164 (1994).
55. Preparation of piperazinylbenzanilide derivativesas 5-HT1D antagonists.
Oxford, A.W.; Mitchell, W.L.; Bradshaw, J.; Clitherow, J.W.; Campbell, I.B. Eur. Pat.
Appl. 533266 (1993).
56. Preparation of azolylpiperazinylbenzanilide derivativesas5-HT1D antagonists.
Oxford, A.W.; Mitchell, W.L.; Bradshaw, J.; Clitherow, J.W.; Carter, M. Eur. Pat. Appl.
533268 (1993).
57. Preparation of benzanilide derivativesas 5-HT1d antagonists. Oxford, A.W.;
Mitchell, W.L.; Bradshaw, J.; Clitherow, J.W. Eur. Pat. Appl. 533267 (1993).
58. Preparation of phenethanolamine derivativesas β2-adrenoreceptor stimulants.
Skidmore, I.F.; Lunts, L.H.C; Finch, H.; Naylor, A.; Campbell, I.B.; Willbe, C.; Mitchell,
W.L.; Swanson, S.; Judkins, B.D. Eur. Pat. Appl. 401966 (1990).
59. Preparation of 4-imidazolylmethyl tetracyclic ketones as serotoninergic S3
antagonists. Bays, D.E.; Coates, I.H.; Bradshaw, J.; Mitchell, W.L. Eur. Pat. Appl.
344015 (1989)

6. 60. Preparation and formulation of (imidazolylmethyl)tetrahydrocarbazolones and
their analogs for treatment of 5-HT function disturbances. Coates, I.H.;
Bradshaw, J.; Bell, J.A.; Humber, D.C.; Ewan, G.B.; Mitchell, W.L.; Price, B.J. U.S.
Patent 4859662 (1989).
61. Preparation of (imidazolylmethyl)tricyclic ketone derivatives as antagonists of
5-hydroxytriptamine. Coates, I.H.; Humber, D.C.; Bell, J.A.; Ewan, G.B.; Oxford,
A.W.; Mitchell, W.L. Eur. Pat. Appl. 317088 (1989).
62. Naphthalene-containing phenethanolamine derivativesuseful as β2-
adrenoreceptor stimulants, and their preparation and pharmaceutical
compositions. Mitchell, W.L.; Skidmore, I.F.; Lunts, L.H.C.; Finch, H.; Naylor, A.;
Hartley, D. Eur. Pat. Appl. 317206 (1989).
63. 3-(Imidazol-2-yl)-1-(indol-3-yl)-1-propanone derivatives as potent and selective
antagonists of 5-hydroxytryptamine (5-HT) at 5-HT3 receptors and a process for
their preparation. Cavalla, D.J.; Mitchell, W.L. Eur. Pat. Appl. 307145 (1989).
64. Arylethanolamine derivatives, processes for their preparation and
pharmaceutical compositions containing them. Skidmore, I.F.; Finch, H.;
Mitchell, W.L.; Naylor, A.; Lunts, L.H.C.; Hartley, D. Eur. Pat. Appl. 286242 (1988).
65. Preparation of 3-(imidazolylmethyl)tetrahydrocarbazolone and their analogs as
psychotropic agents. Coates, I.H.; Bradshaw, J.; Bell, James A.; Humber, D.C.;
Ewan, G.B.; Mitchell, W.L. Ger. Offen. 3740352 (1988).
66. Preparation of imidazolylmethylcarbazolones as central nervous system
agents. Coates, I.H.; Mitchell, W.L.; Humber, D.C.; Bell, J.A.; Ewan, G.B. Ger.
Offen. 3724322 (1988).
67. Synthesis and antiviral properties of 5-(2-substituted vinyl)-6-aza-2'-
deoxyuridines. Mitchell, W.L.; Ravenscroft, P.; Hill, M.L.; Knutsen, L.J.S.;
Judkins, B.D.; Newton, R.F.; Scopes, D. I.C.; J. Med. Chem. 1986, 29, 809-16.
68. Synthesis and antiviral activity of 5-halovinyl-6-aza-2'-deoxyuridines.
Mitchell, W.L.; Ravenscroft, P.; Hill, M.L.; Knutsen, L.J.S.; Newton, R.F.; Scopes,
D.I.C.; Nucleosides Nucleotides 1985, 4, 173-5.
69. Synthesis of C-nucleoside isosteres of 9-(2-hydroxyethoxymethyl)guanine.
Mitchell, W.L.; Hill, M.L.; Newton, R.F.; Ravenscroft, P.; Scopes, D. I.C.; J. Het.
Chem. 1984, 21, 697-9.
70. Synthesis of imidazo-fused bridgehead-nitrogen C-nucleosides via dehydrative
coupling reactions of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonic acid. Knutsen,
L.J.S.; Judkins, B.D.; Mitchell, W.L.; Newton, R.F.; Scopes, D. I.C.; J. Chem. Soc.
Perkin Trans. 1, 1984, 229-38.
71. The synthesis and Diels-Alder reactions of 2-prop-2-enylidene-1,3-dioxolane.
Ley, S.V.; Mitchell, W.L.; Radhakrishnan, T.V.; Barton, D. H.R.; J. Chem. Soc.,
Perkin Trans. 1 , 1981, 1582-4
72. A new synthetic approach towards adriamycin. Barton, D.H.R.; Dawes, C.C.;
Franceschi, G.; Foglio, M.; Ley, S.V.; Magnus, P.D.; Mitchell, W.L.; Temperelli, A.; J.
Chem. Soc., Perkin Trans 1, 1980, 643-7.